BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19509273)

  • 1. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
    Jian W; Yamashita H; Levitt JM; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2009 Jul; 8(7):1772-8. PubMed ID: 19509273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
    Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
    Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
    Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
    Querfeld C; Rizvi MA; Kuzel TM; Guitart J; Rademaker A; Sabharwal SS; Krett NL; Rosen ST
    J Invest Dermatol; 2006 Jul; 126(7):1641-7. PubMed ID: 16645590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
    Morgillo F; Martinelli E; Troiani T; Laus G; Pepe S; Gridelli C; Ciardiello F
    Mol Cancer Ther; 2008 Jun; 7(6):1698-707. PubMed ID: 18566241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
    Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
    Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
    Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
    Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
    Liu D; Kojima T; Ouchi M; Kuroda S; Watanabe Y; Hashimoto Y; Onimatsu H; Urata Y; Fujiwara T
    Mol Cancer Ther; 2009 Apr; 8(4):980-7. PubMed ID: 19372571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
    Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
    Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.
    de Brito Galvao JF; Kisseberth WC; Murahari S; Sutayatram S; Chew DJ; Inpanbutr N
    Am J Vet Res; 2012 Aug; 73(8):1262-72. PubMed ID: 22849687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer.
    Spalding AC; Watson R; Davis ME; Kim AC; Lawrence TS; Ben-Josef E
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6827-33. PubMed ID: 18006785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
    Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
    Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Rademaker-Lakhai JM; Beerepoot LV; Mehra N; Radema SA; van Maanen R; Vermaat JS; Witteveen EO; Visseren-Grul CM; Musib L; Enas N; van Hal G; Beijnen JH; Schellens JH; Voest EE
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4474-81. PubMed ID: 17671132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling.
    Levitt JM; Yamashita H; Jian W; Lerner SP; Sonpavde G
    Mol Cancer Ther; 2010 May; 9(5):1128-35. PubMed ID: 20406945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
    Molè D; Gagliano T; Gentilin E; Tagliati F; Pasquali C; Ambrosio MR; Pansini G; Degli Uberti EC; Zatelli MC
    Endocr Relat Cancer; 2011 Aug; 18(4):439-50. PubMed ID: 21606156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Clin Cancer Res; 2001 Oct; 7(10):3269-75. PubMed ID: 11595724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.